Company Expects Cash Reserves Sufficient Until Q4 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy ZBIO?
As of December 31, 2025, the Company's cash, cash equivalents and investments were $360.5 million. The Company expects that its cash, cash equivalents and investments, as of December 31, 2025, together with the net proceeds received to date in the first quarter of 2026 from sales under our ATM program and the proceeds available from the debt arrangement with investment funds managed by Pharmakon will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2027, and assuming receipt of a potential $75.0 million from the investment funds managed by Pharmakon and $75.0 million from Royalty Pharma contingent upon FDA approval of obexelimab for the treatment of IgG4-RD, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZBIO
Wall Street analysts forecast ZBIO stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.040
Low
19.00
Averages
41.20
High
55.00
Current: 24.040
Low
19.00
Averages
41.20
High
55.00
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zenas BioPharma Reports Q4 EPS Miss and Cash Projections
- Disappointing Earnings: Zenas BioPharma reported a Q4 GAAP EPS of -$4.54, missing expectations by $3.66, indicating significant challenges in profitability that may undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $360.5 million in cash, cash equivalents, and investments, which is projected to fund operating and capital expenditures into Q2 2027, reflecting a degree of financial management capability.
- Future Funding Outlook: Assuming receipt of $75 million from Pharmakon-managed investment funds and another $75 million from Royalty Pharma contingent on FDA approval of obexelimab, the company expects to sustain its cash position into Q4 2027, demonstrating optimism about future cash inflows.
- Market Reaction: Despite the CEO's over $1 million stock purchase, the market's disappointment over late-stage trial data led to a significant stock price drop, indicating investor concerns about the company's future prospects.
See More
Purcell & Lefkowitz Investigates Zenas BioPharma for Potential Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Zenas BioPharma to determine whether the company's directors breached their fiduciary duties in recent corporate actions, potentially affecting shareholder rights.
- Shareholder Rights Focus: The investigation aims to protect Zenas BioPharma shareholders, with the law firm offering free consultations to ensure shareholders are informed about their rights and options, thereby enhancing transparency in corporate governance.
- Legal Support: Purcell & Lefkowitz LLP specializes in representing shareholders nationwide in cases of securities fraud and breaches of fiduciary duty, demonstrating their commitment to safeguarding shareholder interests.
- Potential Impact: Should the investigation confirm misconduct by the board, Zenas BioPharma may face legal repercussions, which could undermine shareholder confidence and adversely affect the company's stock price.
See More
Zenas BioPharma Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Zenas BioPharma investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious governance concerns.
- Disappointing Trial Results: Zenas's January 5, 2026 announcement of 'positive' results from the INDIGO trial was met with skepticism as analysts noted the drug's efficacy likely fell short of commercial viability thresholds, potentially impacting future sales prospects.
- Stock Price Volatility: Following the trial results, Zenas's stock plummeted by 51.86% to $16.61 per share on January 5, 2026, and further declined by 8.49% to $15.20 per share the next day, reflecting a pessimistic market outlook on the company's future.
- CEO Acknowledges Disappointment: During a conference call on January 6, 2026, Zenas's CEO expressed disappointment that the hazard ratio did not meet expectations, which may exacerbate investor concerns and lead to increased legal scrutiny.
See More
Obexelimab Achieves Significant Results in Multiple Sclerosis Trial
- Clinical Trial Success: Obexelimab achieved a 95% relative reduction in new Gd-enhancing T1 lesions in the MoonStone trial for Multiple Sclerosis, demonstrating its potential to transform treatment protocols for patients.
- Good Safety Profile: The trial indicated that Obexelimab was well tolerated with no new safety signals observed, which lays a solid foundation for future market introduction and boosts investor confidence.
- Long-term Efficacy Confirmation: Data from the 24-week follow-up showed sustained efficacy of Obexelimab, with Gd-enhancing T1 lesions decreasing from a baseline of 0.87 to 0.04, indicating its effectiveness and tolerability in long-term treatment.
- Broad Market Prospects: Zenas BioPharma plans to submit a Biologics License Application for Obexelimab to the FDA in 2026, which is expected to create significant market opportunities and further solidify its leadership position in the autoimmune disease sector.
See More
Zenas BioPharma CEO Buys $1M in Stock, Shares Rise 11%
- Executive Purchase: Zenas BioPharma CEO Lonnie Moulder bought over $1M worth of company stock at $17.96 per share, acquiring 57,000 shares, which reflects strong confidence in the company's future prospects.
- Increased Stake: Following this transaction, Moulder's total holdings in Zenas have risen to nearly 1.7 million shares, reinforcing his position as founder and chairman, which may enhance investor trust in the company.
- Upcoming Catalysts: Zenas is scheduled to present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, which is expected to draw investor attention to the mid-stage trial results for its lead asset targeting systemic lupus erythematosus.
- Market Reaction: Despite earlier declines in Zenas's stock price due to disappointing late-stage trial results for its candidate against IgG4-related disease, the CEO's stock purchase may improve market sentiment and boost the share price.
See More
Pomerantz Investigates Zenas BioPharma After 51.86% Stock Drop
- Stock Price Plunge: Zenas BioPharma's stock dropped $17.89, or 51.86%, to close at $16.61 on January 5, 2026, following the announcement of its IgG4-RD trial results, indicating market concerns over the drug's commercial viability.
- Trial Results Disappointment: Although Zenas characterized the INDIGO trial results as 'positive,' analysts noted that the drug's efficacy fell short of the necessary threshold for commercial success, leading to diminished investor confidence.
- CEO Acknowledgment of Disappointment: During a conference call on January 6, 2026, Zenas's CEO admitted that the hazard ratio did not meet expectations, causing the stock to fall another $1.41, or 8.49%, further heightening concerns about the company's future.
- Legal Investigation Launched: Pomerantz LLP is investigating whether Zenas and its executives engaged in securities fraud or other unlawful business practices, which could significantly impact the company's future legal liabilities and financial health.
See More
Zenas BioPharma Reports Q4 EPS Miss and Cash Projections
- Disappointing Earnings: Zenas BioPharma reported a Q4 GAAP EPS of -$4.54, missing expectations by $3.66, indicating significant challenges in profitability that may undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $360.5 million in cash, cash equivalents, and investments, which is projected to fund operating and capital expenditures into Q2 2027, reflecting a degree of financial management capability.
- Future Funding Outlook: Assuming receipt of $75 million from Pharmakon-managed investment funds and another $75 million from Royalty Pharma contingent on FDA approval of obexelimab, the company expects to sustain its cash position into Q4 2027, demonstrating optimism about future cash inflows.
- Market Reaction: Despite the CEO's over $1 million stock purchase, the market's disappointment over late-stage trial data led to a significant stock price drop, indicating investor concerns about the company's future prospects.
See More
Purcell & Lefkowitz Investigates Zenas BioPharma for Potential Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Zenas BioPharma to determine whether the company's directors breached their fiduciary duties in recent corporate actions, potentially affecting shareholder rights.
- Shareholder Rights Focus: The investigation aims to protect Zenas BioPharma shareholders, with the law firm offering free consultations to ensure shareholders are informed about their rights and options, thereby enhancing transparency in corporate governance.
- Legal Support: Purcell & Lefkowitz LLP specializes in representing shareholders nationwide in cases of securities fraud and breaches of fiduciary duty, demonstrating their commitment to safeguarding shareholder interests.
- Potential Impact: Should the investigation confirm misconduct by the board, Zenas BioPharma may face legal repercussions, which could undermine shareholder confidence and adversely affect the company's stock price.
See More
Zenas BioPharma Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Zenas BioPharma investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious governance concerns.
- Disappointing Trial Results: Zenas's January 5, 2026 announcement of 'positive' results from the INDIGO trial was met with skepticism as analysts noted the drug's efficacy likely fell short of commercial viability thresholds, potentially impacting future sales prospects.
- Stock Price Volatility: Following the trial results, Zenas's stock plummeted by 51.86% to $16.61 per share on January 5, 2026, and further declined by 8.49% to $15.20 per share the next day, reflecting a pessimistic market outlook on the company's future.
- CEO Acknowledges Disappointment: During a conference call on January 6, 2026, Zenas's CEO expressed disappointment that the hazard ratio did not meet expectations, which may exacerbate investor concerns and lead to increased legal scrutiny.
See More
Obexelimab Achieves Significant Results in Multiple Sclerosis Trial
- Clinical Trial Success: Obexelimab achieved a 95% relative reduction in new Gd-enhancing T1 lesions in the MoonStone trial for Multiple Sclerosis, demonstrating its potential to transform treatment protocols for patients.
- Good Safety Profile: The trial indicated that Obexelimab was well tolerated with no new safety signals observed, which lays a solid foundation for future market introduction and boosts investor confidence.
- Long-term Efficacy Confirmation: Data from the 24-week follow-up showed sustained efficacy of Obexelimab, with Gd-enhancing T1 lesions decreasing from a baseline of 0.87 to 0.04, indicating its effectiveness and tolerability in long-term treatment.
- Broad Market Prospects: Zenas BioPharma plans to submit a Biologics License Application for Obexelimab to the FDA in 2026, which is expected to create significant market opportunities and further solidify its leadership position in the autoimmune disease sector.
See More
Zenas BioPharma CEO Buys $1M in Stock, Shares Rise 11%
- Executive Purchase: Zenas BioPharma CEO Lonnie Moulder bought over $1M worth of company stock at $17.96 per share, acquiring 57,000 shares, which reflects strong confidence in the company's future prospects.
- Increased Stake: Following this transaction, Moulder's total holdings in Zenas have risen to nearly 1.7 million shares, reinforcing his position as founder and chairman, which may enhance investor trust in the company.
- Upcoming Catalysts: Zenas is scheduled to present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, which is expected to draw investor attention to the mid-stage trial results for its lead asset targeting systemic lupus erythematosus.
- Market Reaction: Despite earlier declines in Zenas's stock price due to disappointing late-stage trial results for its candidate against IgG4-related disease, the CEO's stock purchase may improve market sentiment and boost the share price.
See More
Pomerantz Investigates Zenas BioPharma After 51.86% Stock Drop
- Stock Price Plunge: Zenas BioPharma's stock dropped $17.89, or 51.86%, to close at $16.61 on January 5, 2026, following the announcement of its IgG4-RD trial results, indicating market concerns over the drug's commercial viability.
- Trial Results Disappointment: Although Zenas characterized the INDIGO trial results as 'positive,' analysts noted that the drug's efficacy fell short of the necessary threshold for commercial success, leading to diminished investor confidence.
- CEO Acknowledgment of Disappointment: During a conference call on January 6, 2026, Zenas's CEO admitted that the hazard ratio did not meet expectations, causing the stock to fall another $1.41, or 8.49%, further heightening concerns about the company's future.
- Legal Investigation Launched: Pomerantz LLP is investigating whether Zenas and its executives engaged in securities fraud or other unlawful business practices, which could significantly impact the company's future legal liabilities and financial health.
See More
